How KLOW blend works
GLOW plus KPV: a four-ingredient community blend with no human study of the combination found.
Also called: KLOW, KLOW blend, KLOW 80, KLOW stack, klow-blend.
Community blends · Unapproved community blend of GHK-Cu, BPC-157, TB-500 and KPV; contents and ratios vary.
The proposed rationale combines copper-linked tissue remodeling, BPC-related vessel signaling, thymosin-related cell movement and KPV-related inflammatory signaling. These are separate ingredient findings. No human study establishes synergy or the safety of mixing all four.
- GHK-Cu: Skin and wound research concerns topical products or animal experiments. It does not validate an injected KLOW dose.
- BPC-157: Laboratory work includes tendon repair and vessel-growth signaling. Small uncontrolled human reports do not establish blend efficacy.
- TB-500 / reported thymosin ingredient: Full-length thymosin beta-4 has separate human research. Those results cannot be assigned to the shorter TB-500 fragment or an unidentified mixed vial.
- KPV: KPV reduced inflammatory signaling in cells and colitis in mice given KPV in drinking water. This does not establish injected gut benefits in humans.
Half-life: Unknown for the blend; no human combination pharmacokinetic study found.
Related to KLOW blend
- Wolverine stack (BPC-157 + TB-500): An unapproved recovery blend with no controlled human trial of the premixed product.
- GLOW blend (GHK-Cu + BPC-157 + TB-500): An unapproved skin-and-recovery blend with no human combination study found.
Sources
- Cellulitis, NHS · NHS · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Evaluation of KPV-related Bulk Drug Substances (KPV (free base) and KPV acetate) for Inclusion on the 503A Bulk Drug Substances List, FDA · 2026
- Federal Register: nonbinding draft HHS interim policy, October 30 2026, 2026
- HHS 503A peptide interim enforcement policy and conditions, October 30 2026, 2026
- July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), FDA · 2026
- July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate), FDA · FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Using intramuscular injections in people on oral anticoagulants, NHS Specialist Pharmacy Service · NHS Specialist Pharmacy Service · 2023
- Allergies, NHS
- Eating, Diet, & Nutrition for Wilson Disease, NIDDK
- Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases., Froum S et al. · Frontiers in oral health · 2026
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain., Lee E et al. · Alternative therapies in health and medicine · 2021
- Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin., Miller TR et al. · Archives of facial plastic surgery · 2006
Sources checked: 2026-11-03.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.